ScreenerHero

ABSI Absci Corporation

NAS · US · Healthcare · Biotechnology · absci.com
9.220USD-10.22%Mkt Cap: 1.58B $P/E: —

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.58B USD
Enterprise Value1.57B USD
Revenue (TTM)1.56M USD
Gross Profit-84.23M USD
Net Income (TTM)-115.18M USD
Revenue/Share0.01 USD
Last Price9.220 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees140
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.21
PEG—
EV/EBITDA-13.10
EV/Revenue1002.67
P/S1129.07
P/B7.16
EPS (TTM)-0.70
EPS (Forward)-0.68
52W Range
2.24072% of range12.00
52W High12.00 USD
52W Low2.240 USD
Profitability
Gross Margin0.00%
Oper. Margin-10741.51%
EBITDA Margin0.00%
Profit Margin-4113.68%
ROE-60.80%
ROA-53.25%
Growth
Revenue Growth-46.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-92.92M USD
CapEx (TTM)1.11M USD
FCF Margin-3240.98%
FCF Yield-3.20%
Net Debt-197.31M USD
Net Debt/EBITDA1.65
Balance Sheet
Debt/Equity0.03
Current Ratio10.63
Quick Ratio10.26
Book Value/Sh1.44 USD
Cash/Share1.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.40 USD
Upside (mean)+56.2%
Target Range10.00 USD – 17.00 USD
10.00+56.2% to mean17.00
# Analysts10
Ownership
Shares Out.171.61M
Float163.79M
Insiders11.84%
Institutions87.30%
Short Interest
Short Ratio13.3d
Short % Float26.41%
Short % Out.21.71%
Shares Short37.26M
Short (prev mo.)37.42M
Technical
SMA 509.075 (+1.6%)
SMA 2005.902 (+56.2%)
Beta2.28
S&P 52W Chg16.45%
Avg Vol (30d)3.68M
Avg Vol (10d)4.41M
Technical Indicators
RSI (14)46.6
MACD0.4156
MACD Signal0.4203
MACD Hist.-0.0047
BB Upper11.79 USD
BB Middle9.665 USD
BB Lower7.539 USD
BB Width43.99%
ATR (14)0.8522 USD
Vol Ratio (20d)1.47x